CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Doxazosin 4mg/day +2 moredrug
Likely dose
Doxazosin 4mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01730846
NCT01730846Phase 2Completed
CompareCT.gov

Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

Yale University·interventional·Posted Nov 21, 2012·Updated Feb 20, 2018

In Brief

A Phase 2 clinical trial evaluating Doxazosin 4mg/day, Placebo, and 1 other intervention for Smoking. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 21, 2012
Enrollment StartFeb 1, 2013
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.6 years ago

Interventions

Doxazosin 4mg/daydrug

4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.

Placebodrug

Placebo

Doxazosin 8mg/daydrug

8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.